DiaMedica Posts Narrower Loss in Q2

DiaMedica Therapeutics (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing treatments for serious unmet medical needs, released its second quarter results on August 12, 2025. The headline news was a net loss per share of $(0.18) (GAAP) for the quarter, which surpassed the analyst estimate of $(0.19) (GAAP). No revenue was reported as expected, consistent with its pre-commercial status. Operating expenses were higher compared to the same period in the prior year, yet the company achieved key clinical milestones and the closing of a $30.1 million private placement in July 2025, securing a financial runway well into the second half of 2027. Overall, the period featured notable progress in DiaMedica's drug pipeline and financial position, balanced by increased costs typical for its development stage. Source: Analyst estimates for the quarter provided by FactSet. DiaMedica is charting a path to develop novel therapies for diseases with limited treatment options. Its lead product, DM199, is a recombinant protein designed to treat acute ischemic stroke (AIS) and preeclampsia (PE). Both conditions represent significant unmet needs, with few safe or effective treatments currently available.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool